Project Grant R44AI192249
Award Date 8/13/25
Completion Date 7/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Albany, CA 94710, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Emmune Inc., a biotechnology company based in Cambridge, Massachusetts. The grant will support pre-clinical IND-enabling studies for a long-acting recombinant protein therapeutic called ECD4-IG, which is being developed as a potential treatment for HIV. The key activities include conducting in vitro assays...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $862,398 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant, running from August 1, 2025 to July 31, 2030, will support research to selectively target and eliminate the HIV/SIV reservoir in T follicular helper cells using novel anti-PD-1 chimeric antigen receptor (CAR) T cells. The research aims to develop safer and more...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $368,750 Project Grant to the Veterans Medical Research Foundation of San Diego through the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The project aims to determine the mechanisms by which the short isoform of the BST2 protein, which has broad antiviral activity, is antagonized by HIV-1 and HIV-2. This research seeks to understand how HIV evades this key cellular defense and the...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,568,644 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Wistar Institute of Anatomy and Biology, a non-profit biomedical research institute. The award aims to develop an individualized HIV cure strategy that combines enhanced neutralizing antibody responses, antiviral adaptive NK cells, and engineered cell-mediated effector strategies. The goal is to characterize...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant to Yale University for the "Molecular Investigations of HIV-1 Maturation Pathways and Inhibitor Actions in situ" research project. The grant, funded under NIAID's Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to use advanced in-situ cryo-electron microscopy and tomography techniques to visualize the structural transitions of the HIV-1 virus during the maturation...